The category of compounds identified as Vmn2r12 Inhibitors consists of chemicals that, while not directly targeting Vmn2r12, exert their influence on various signaling pathways and cellular processes that could, in turn, modulate the activity or expression of Vmn2r12. These compounds operate through diverse mechanisms, such as antagonism of specific receptors, inhibition of kinase activity, modulation of calcium signaling, and alteration of cytoskeletal dynamics. Through these mechanisms, they have the capacity to indirectly impact the signal transduction pathways and cellular contexts in which Vmn2r12 functions, thereby offering a strategic approach to studying and potentially modulating the activity of this protein.
The selection of these compounds reflects a nuanced understanding of cellular signaling as a highly interconnected network, where changes in one part of the system can have widespread effects on other components. By targeting various nodes within this network-such as GPCRs, kinases, and calcium signaling pathways-the listed chemicals can alter the cellular milieu and the flow of biochemical signals within the cell. This, in turn, can influence the activity of Vmn2r12, even in the absence of direct interaction with the protein. Such an approach underscores the complexity of cellular signaling and the potential for indirect strategies to elucidate the functions of specific proteins within this web of interactions. Through the modulation of signaling pathways that Vmn2r12 is either directly or indirectly involved in, these compounds provide valuable tools for probing the biological roles of Vmn2r12 and for exploring the intricate regulatory mechanisms that govern cellular response mechanisms.
SEE ALSO...
Items 1 to 10 of 17 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $90.00 $349.00 | 1 | |
A selective adenosine A2A receptor antagonist, potentially affecting GPCR-mediated signaling pathways that Vmn2r12 could be part of. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A | 50 mg 500 mg | $68.00 $357.00 | 11 | |
Clozapine is an atypical antipsychotic drug that acts as a serotonin antagonist. Its inhibition of serotonin receptors could disrupt signaling pathways that Vmn2r121 is involved in, thereby inhibiting the protein's function. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
A broad-spectrum protein kinase C (PKC) inhibitor, which could affect signaling pathways intersecting with Vmn2r12's function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibits ROCK (Rho-associated protein kinase), potentially impacting actin cytoskeleton dynamics related to Vmn2r12 signaling. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
Inhibits myosin light chain kinase (MLCK), potentially affecting cellular processes that influence Vmn2r12 signaling. | ||||||
Ritanserin | 87051-43-2 | sc-203681 sc-203681A | 10 mg 50 mg | $87.00 $306.00 | 2 | |
Ritanserin is a selective serotonin receptor antagonist that could inhibit Vmn2r121 by blocking serotonin receptors involved in the same signaling pathways as Vmn2r121, leading to an inhibition of its activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
Inhibits the TGF-beta type I receptor ALK5, potentially affecting signaling pathways that Vmn2r12 is involved in. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
Ondansetron is a serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting. It could inhibit Vmn2r121 by blocking the serotonin receptors that may be involved in the same pathways, potentially inhibiting the functionality of Vmn2r121. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
Inhibits the FGFR1 tyrosine kinase, potentially modulating signaling pathways that intersect with Vmn2r12 activity. | ||||||
Ketanserin | 74050-98-9 | sc-279249 | 1 g | $700.00 | ||
Ketanserin is a selective serotonin 5-HT2A receptor antagonist. By inhibiting these receptors, it could prevent the activation of signaling cascades that Vmn2r121 might be a part of, resulting in the inhibition of Vmn2r121 activity. | ||||||